Research Perspectives:

CDK9 INHIBITORS: a promising combination partner in the treatment of hematological malignancies

Daniel Morillo, Gala Vega and Victor Moreno _

PDF  |  Full Text  |  How to cite  |  Press Release

Oncotarget. 2023; 14:749-752. https://doi.org/10.18632/oncotarget.28473

Metrics: PDF 156 views  |   Full Text 1047 views  |   ?  


Daniel Morillo1, Gala Vega1 and Victor Moreno2

1 Division of Hematology, START Madrid-FJD, Hospital Fundación Jiménez Díaz, Madrid, Spain

2 Division of Oncology, START Madrid-FJD, Hospital Fundación Jiménez Díaz, Madrid, Spain

Correspondence to:

Victor Moreno, email: [email protected]

Keywords: cyclin-dependent kinases (CDK); CDK9; hematological malignancies

Received: April 18, 2023     Accepted: June 21, 2023     Published: August 07, 2023

Copyright: © 2023 Morillo et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Most hematological malignancies are characterized by overexpression of certain cancer promoting genes, such as MYC, MCL1 and cyclin D1. Preclinical studies in animal models have shown that CDK9 inhibitors supress the transcription of these anti-apoptotic and pro-survival proteins, and suggest their potential synergism with other drugs. In its first in-human trial, enitociclib demonstrated clinical activity in a small cohort of patients with high grade B lymphoma with MYC and BCL2 and/or BCL6 rearrangements, inducing complete responses in 2 of 7 subjects (29%) in monotherapy. These data suggest CDK9 inhibitors could play a role in the treatment of hematological diseases and could be a great ally when combined with other therapeutic approaches.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 28473